Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract cancer (BTC).

Jun 3, 2025 - 06:00
Zymeworks’ zanidatamab gains approval in China for biliary tract cancer
China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract cancer (BTC).

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow